Dr. Robert P. Lagrone, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 421
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Vanderbilt University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
TN license MD20971
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 421
- Services billed
- 192,713
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 103,600 | 30 |
| Injection, tocilizumab, 1 mg | 42,231 | 12 |
| Injection, infliximab, excludes biosimilar, 10 mg | 30,533 | 66 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 5,625 | 14 |
| Injection, denosumab, 1 mg | 1,320 | 13 |
| Administration of chemotherapy into vein, 1 hour or less | 705 | 107 |
| Infusion, normal saline solution, 250 cc | 701 | 107 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 582 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 499 | 303 |
| Administration of chemotherapy into vein, each additional hour | 466 | 71 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Nashville, TN | 944 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Nashville, TN | 543 |
| Methotrexate (methotrexate sodium) Other prescribers in Nashville, TN | 406 |
| Duloxetine Hcl Other prescribers in Nashville, TN | 383 |
| Tizanidine Hcl Other prescribers in Nashville, TN | 286 |
| Tramadol Hcl Other prescribers in Nashville, TN | 261 |
| Gabapentin Other prescribers in Nashville, TN | 253 |
| Trazodone Hcl Other prescribers in Nashville, TN | 250 |
| Hydroxychloroquine Sulfate Other prescribers in Nashville, TN | 248 |
| Leflunomide Other prescribers in Nashville, TN | 147 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 119 payments worth $2,323 in total to this clinician.
| AbbVie Inc. | $399 |
|---|---|
| Novartis Pharmaceuticals Corporation | $382 |
| UCB, Inc. | $309 |
| Amgen Inc. | $240 |
| AstraZeneca Pharmaceuticals LP | $227 |
| Janssen Biotech, Inc. | $214 |
| Pfizer Inc. | $101 |
| Organon LLC | $99.47 |
| Food and Beverage | $2,245 |
|---|---|
| Education | $77.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 8, 2025 | Education TREMFYA · Immunology · in-kind | $77.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $23,899 in research payments for these studies, mostly to the institutions running them.
- A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Daiichi Sankyo Inc. · Completed · NCT05638802
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.